knowledge -WSS

knowledge

author：comprehensive 2025-09-27 16:17:07 - browse：26

A new treatment for Alzheimer’s disease developed by Eli Lilly slowed patients’ rate of cognitive and functional decline by 35% compared to placebo, the company said Wednesday, paving the way for a submission to the Food and Drug Administration and boosting hopes for a new class of Alzheimer’s drugs.

But the positive outcome of the study involving the drug, called donanemab, could be tempered by the deaths of two patients, and possibly a third, from a type of brain swelling caused by these drugs.

The results of the study were reported in a press release and have not yet been reviewed by outside scientists. Lilly said the data will be used to file for full approval with the FDA before the end of June. If cleared, donanemab will compete with another new Alzheimer’s treatment, Leqembi, made by Eisai and Biogen, that secured FDA approval in January.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Malaria cases in Florida and Texas: Here’s what you need to know
Next article： How artificial intelligence is being used to detect, treat cancer

WSS

Organ transplantation is at a crossroads. Major reform is needed

Depression: FDA OKs Otsuka Pharmaceuticals digital therapeutic

Providers still hesitate to prescribe buprenorphine, study finds

Drug companies' payments and gifts affect physicians' prescribing

What to know about Saharan dust affecting the US and how it can affect health

As Taiwan prepares for anti

hotspot

knowledge

explore

Over 800 arrested across France in 3rd night of riots after fatal police shooting of teen

Multiple sclerosis has subtypes with different best treatments: study

Psychedelics group wrestles with new pharma identity

New rules on organ donation and transplantation 'will bring chaos'

Cancer drug shortages should be causing more outrage

What to know about Saharan dust affecting the US and how it can affect health

How one medical school became remarkably diverse

Harvard scientists, with Google, unveil the most detailed brain map ever

Hepatitis C has a cure — but many Americans still lack access to it

Providers still hesitate to prescribe buprenorphine, study finds

Wikipedia

Medicare Advantage 2025 payments will dip, Biden administration says

7 of the most gruesome medical devices in history

Contact tracing may help avoid another lockdown. Can it work in the U.S.?

Elizabeth Warren probes abortion access

Harvard scientists, with Google, unveil the most detailed brain map ever

Insurer loopholes limit power of law against surprise medical bills

hotspot

focus

explore

focus